Dr. Zhang is a postdoctoral research trainee in the department of ophthalmology at the University of Tennessee Health Science Center in Memphis.
The technique she is researching is designed to deliver high intraocular concentrations of chemotherapy to treat extensive disease while minimizing system exposure, according to the release. She hopes her research may eventually make superselective intraophthalmic artery chemotherapy the standard treatment for retinoblastoma, as opposed to the current treatment option of conventional chemotherapy.
The Knights Templar Eye Foundation is an organization “committed to preserving sight and preventing blindness since its founding in 1955,” according to its website. As of August 2012, the foundation has spent $137 million on research, patient care and education.
Related Articles on Ophthalmology:
Massachusetts Eye and Ear Partners With Joslin Diabetes Center for Eye Care
UC Irvine Receives Grant to Help Create Stem Cell Treatments for Retinitis Pigmentosa
